Natera Inc
NTRA
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 7, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
189.3% downsideOvervalued by 189.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.99 Billion |
|---|---|
| Enterprise Value | $31.16 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.52 |
| Beta | 1.57 |
| Outstanding Shares | 141,502,000 |
Return
| Return on Equity | -12.76% |
|---|---|
| Return on Assets | -8.66% |
| Return on Invested Capital | -14.44% |
Valuation & Multiples
| P/E Ratio | -139.66 |
|---|---|
| PEG | -514.92 |
| Price to Sales | 12.46 |
| Price to Book Ratio | 17.65 |
| Enterprise Value to Revenue | 12.46 |
| Enterprise Value to EBIT | -104.96 |
| Enterprise Value to Net Income | -138 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1353▲ 47.37% |
|---|---|
| Total Calls | 535,962▲ 11.87% |
| Total Puts | 608,500▲ 91.96% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.66%▲ 1.37% |
|---|---|
| Total Invested | $26.52B▼ 12.36% |
| Investors Holding | 781▼ 29.00% |
ESG Score
No data
About Natera Inc
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operat...
Relevant Senate Committees
As the most powerful economic committee, it controls taxation and entitlement spending, crucially including Medicare pricing. Medicare reimbursement rates are vital for Natera's revenue, and tax policy directly impacts its profitability and corporate valuation.
This committee allocates federal discretionary spending. Its subcommittees determine funding for scientific research, federal healthcare programs (like Medicare/Medicaid), and agencies relevant to Natera, directly influencing research grants and reimbursement for its tests.
This committee directly regulates the FDA (which oversees medical devices/diagnostics) and the NIH (critical for research funding). Labor laws also directly impact Natera's workforce. This is a primary regulatory body for Natera's industry.
This committee's oversight of antitrust laws directly impacts potential mergers and acquisitions in the biotech sector. Critically, its jurisdiction over intellectual property is paramount for Natera's proprietary genetic testing technologies.